3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Prostatic Neoplasms
2
Uterine Cervical Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Ovarian Neoplasms
1
Neoplasms, Squamous Cell
1
Melanoma
1
Esophageal Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
Cisplatin
27
pembrolizumab
21
Brachytherapy
16
Radiotherapy
14
Carboplatin
10
Radiation
8
Paclitaxel
8
Platinum
7
1,2-diaminocyclohexaneplatinum II citrate
7
Topotecan
6
fludarabine
5
atezolizumab
5
Magnetic Resonance Spectroscopy
5
Fluorodeoxyglucose F18
5
Cyclophosphamide
5
Bevacizumab
5
durvalumab
4
Nivolumab
4
Gemcitabine
4
tremelimumab
3
temsirolimus
3
human papillomavirus vaccine, L1 type 16, 18
3
aldesleukin
3
Radiotherapy, Intensity-Modulated
3
Papillomavirus Vaccines
3
Ipilimumab
3
Interleukin-2
3
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
3
Docetaxel
3
Biopsy
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Uterine Cervical Neoplasms
×
High-Intensity Focused Ultrasound Ablation
×
Clear all
NCT04116320
2025-07-14
AM-003
University of Virginia
Phase 1
Terminated
5 enrolled